Information Provided By:
Fly News Breaks for September 17, 2018
NUVA
Sep 17, 2018 | 07:54 EDT
Canaccord analyst Kyle Rose raised his price target on NuVasive to $80 from $70 following meetings with management. The analyst believes the shares offer a compelling risk/reward setup in medtech citing its conservative guidance, robust new product flow, stable U.S. spine market share, and improving investor sentiment. Rose reiterated his Buy rating on NuVasive shares.
News For NUVA From the Last 2 Days
There are no results for your query NUVA